In fact, a study evaluated associations and potential correlations with clinical efficacy of the PD-L1 SP263 assay scored with the TAP algorithm (referred to as TIC [Tumor and Immune Cell]) at 5% cutoff and the PD-L1 22C3 assay scored with the CPS algorithm at 1% cutoff in gastroesophageal adenocarcinoma. Here, CD274 is linked to neoplasm.